Barrington Research Reiterates Haemonetics Outperform, $73 PT
Barrington Research reiterated its Haemonetics (NYSE: HAE) Outperform rating and $73 price target in a research report published today.
In the report, Barrington Research states, "We continue to have confidence in the long-term competitive position of HAE within the blood products industry."
Shares of Haemonetics closed today at $64.96, down 0.11% from Monday's market close.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.